Engineered galactose oxidase variant enzymes
The present invention provides engineered galactose oxidase (GOase) enzymes, polypeptides having GOase activity, and polynucleotides encoding these enzymes, as well as vectors and host cells comprising these polynucleotides and polypeptides. Methods for producing GOase enzymes are also provided. The present invention further provides compositions comprising the GOase enzymes and methods of using the engineered GOase enzymes. The present invention finds particular use in the production of pharmaceutical and other compounds.
1. An engineered galactose oxidase comprising a polypeptide sequence having at least 95% sequence identity to SEQ ID NO: 1912, or a functional fragment thereof, wherein said engineered galactose oxidase comprises substitutions as compared to SEQ ID NO: 1912 in said polypeptide sequence at positions 291, 375, 453, and 465, and wherein the amino acid positions of said polypeptide sequence are numbered with reference to SEQ ID NO: 1912.
2. The engineered galactose oxidase of claim 1 , wherein said engineered galactose oxidase further comprises production of 2-ethynylglyceraldehyde with increased enantiomeric excess of the R-stereoisomer as compared to wild-type F. graminearium galactose oxidase.
3. The engineered galactose oxidase of claim 1 , wherein said engineered galactose oxidase comprises substitutions as compared to SEQ ID NO: 1912 in said polypeptide sequence of 291Y, 375D, 453V, and 465L and wherein the amino acid positions of said polypeptide sequence are numbered with reference to SEQ ID NO: 1912.
4. The engineered galactose oxidase of claim 1 , wherein said polypeptide sequence has at least 95% sequence identity to SEQ ID NO: 2080, and wherein said engineered galactose oxidase further comprises at least one substitution or substitution set at one or more positions in said polypeptide sequence selected from 24, 47, 63, 78, 95, 119, 121, 197, 207, 214, 219, 220, 249, 294, 324, 365, 408, 414, 437, 480, 485, 520, 556, 571, 598, 600, and 626, wherein the amino acid positions of said polypeptide sequence are numbered with reference to SEQ ID NO: 2080.
5. The engineered galactose oxidase of claim 1 , wherein said polypeptide sequence has at least 95% sequence identity to SEQ ID NO: 2080, and wherein said engineered galactose oxidase further comprises at least one substitution or substitution set at one or more positions in said polypeptide sequence selected from 14/130/257/472, 14/257, 24, 29, 29/136, 29/136/197/436, 29/136/436, 29/136/436/453, 29/197, 29/197/342/436, 29/197/436, 29/197/436/453, 29/197/453, 29/436, 29/436/472, 29/453, 29/472, 43, 63, 95, 119, 130/421, 136, 136/197/436, 136/197/436/453, 136/436, 144, 197, 197/436, 197/436/453, 197/436/472, 197/453, 214, 219, 249, 257, 257/472, 297, 359, 436, 437, 460, 485, 495, 520, 556, 560, 567, and 592, wherein the amino acid positions of said polypeptide sequence are numbered with reference to SEQ ID NO: 2080.
6. The engineered galactose oxidase of claim 1 , wherein said polypeptide sequence has at least 95% sequence identity to SEQ ID NO: 2300, and wherein said engineered galactose oxidase further comprises at least one substitution or substitution set at one or more positions in said polypeptide sequence selected from 24, 24/51/63/197/359, 24/119/197, 24/197/249/437, 43/197/359, 43/249, 63, 63/67/197/571, 63/67/214/556, 63/119/197, 63/119/197/207/214, 63/119/197/339/341, 63/119/197/556, 63/119/197/556/571, 63/119/556, 63/197, 63/197/207/556, 63/197/207/556/571, 63/197/214/571, 63/197/249/495, 63/197/556/571, 95/197, 95/219/359, 119, 119/197, 119/197/207/571, 119/197/214, 119/197/214/556, 119/197/214/571, 119/197/339, 119/197/556, 119/197/556/571, 119/197/571, 119/207/556/571, 197, 197/207, 197/207/214/471, 197/214, 197/219, 197/339/556/571, 197/556, 197/556/571, 197/571, 214/249/359, 219, and 556, wherein the amino acid positions of said polypeptide sequence are numbered with reference to SEQ ID NO: 2080.
7. The engineered galactose oxidase of claim 1 , wherein said polypeptide sequence has at least 95% sequence identity to SEQ ID NO: 2300, and wherein said engineered galactose oxidase further comprises at least one substitution or substitution set at one or more positions in said polypeptide sequence selected from 194/330/495, 196, 246/408/442/462, 246/442, 292, 327, 327/329, 330, 407, 442, 442/462/515, 462/583, 465, 498, and 583, wherein the amino acid positions of said polypeptide sequence are numbered with reference to SEQ ID NO: 2080.
8. The engineered galactose oxidase of claim 1 , wherein said polypeptide sequence has at least 95% sequence identity to SEQ ID NO: 2424, and wherein said engineered galactose oxidase further comprises at least one substitution or substitution set at one or more positions in said polypeptide sequence selected from 14, 14/24/36/96, 14/24/36/296/424/560, 14/24/78/120/258, 14/24/92/96/99/408, 14/24/96/258/626, 14/24/258/560, 14/78/120/258/488/560/626, 14/92/96/99, 14/92/96/99/120/537, 14/92/96/120/376, 14/92/99/120/537, 14/95/120/296/480/560, 14/120/480/626, 14/258, 14/258/296/560, 14/376/560, 14/408, 23/36/92/95/96, 23/36/92/95/99/408/596, 23/36/408/428, 23/36/537/596, 23/218/537, 23/408/596, 24, 24/36/46/99/426/532/549, 24/36/95/96, 24/36/95/99/404/426/485, 24/36/96/99/532/549, 24/36/99/404/426/532/549/600, 24/36/120/296/480/560, 24/36/404/426/532, 24/36/404/480/485/532/560/600, 24/46/92/404/426/532, 24/46/92/426/532, 24/46/92/426/549, 24/46/95/99/426/532, 24/46/99/426/549/600, 24/46/404/426/485/532, 24/96/404/426, 24/99, 24/99/404/485/532/600, 24/296, 24/296/324/480, 24/404/426/532, 24/404/480/485, 24/404/480/532/549/560, 36, 36/92/95/99/404/426/560, 36/92/95/428/596, 36/92/96/408/428/540/596, 36/92/485, 36/258/296, 36/258/296/324/433/626, 36/404, 36/404/426/549/600, 36/408/537/596, 36/408/596, 36/426/485/600, 46, 46/92/560, 92, 92/95/485/532/549/560, 92/99/218/560, 95, 95/120/296/626, 95/404/426/532, 96, 96/99, 96/258/560/626, 99, 99/404/426/560, 99/426/480/485, 120, 120/324/480/560, 218, 218/408, 296/324, 296/324/560, 324/560, 404, 404/485/600, 408, 480, 485, 532, 537, 537/640, 549, 549/560, 560, 596, and 600, wherein the amino acid positions of said polypeptide sequence are numbered with reference to SEQ ID NO: 2080.
9. The engineered galactose oxidase of claim 1 , wherein said polypeptide sequence has at least 95% sequence identity to SEQ ID NO: 2424, and wherein said engineered galactose oxidase further comprises at least one substitution or substitution set at one or more positions in said polypeptide sequence selected from 14, 14/24/36/96, 14/24/36/296/424/560, 14/24/78/120/258, 14/24/99/218/408/537/560, 14/24/258/560, 14/46/47/376, 14/46/96/99/560, 14/92/96/99/376/560, 14/92/96/120/376, 14/92/96/376, 14/92/99/120/218/408, 14/92/99/120/537, 14/92/99/218/408, 14/92/218/408, 14/95/120/296/480/560, 14/376, 14/376/537, 14/376/560, 14/408, 14/537, 23/36, 23/36/92/95/96, 23/36/92/95/99/408/596, 23/36/96/408/596/640, 23/36/408/428, 23/36/537/540/640, 23/36/537/596, 23/218/596/640, 24, 24/36/46/99/426/532/549, 24/36/95/96, 24/36/95/99/404/426/485, 24/36/96/99/532/549, 24/36/120/296/480/560, 24/36/404/426/532, 24/36/404/480/485/532/560/600, 24/46/92/404/426/532, 24/46/92/426/532, 24/46/92/426/549, 24/46/95/99/426/532, 24/46/99/426/549/600, 24/46/404/426/485/532, 24/96/404/426, 24/96/404/426/560, 24/99, 24/296, 24/404/426/532, 24/404/480/485, 24/532, 36, 36/92/95/428/596, 36/95/96, 36/99/426/485/600, 36/258/296, 36/258/296/324/433/626, 36/404, 36/404/426/549/600, 36/408, 36/408/537/596, 36/426/485/600, 46/92/560, 78, 92, 92/95/485/532/549/560, 92/96, 92/99/120, 92/99/218/560, 92/218, 92/404, 95, 96, 96/99, 99, 99/426/480/485, 99/640, 120, 120/324/480/560, 120/376, 218/537/596, 218/596, 258, 296, 296/324, 296/324/560, 296/480/560, 324, 361, 404, 404/426/485, 408/596, 424, 426/485, 426/532/549, 480, 532, 537/640, 549, 549/560, 560, 600, 626, and 640, wherein the amino acid positions of said polypeptide sequence are numbered with reference to SEQ ID NO: 2080.
10. The engineered galactose oxidase of claim 1 , wherein said engineered galactose oxidase is a variant engineered polypeptide set forth in SEQ ID NOS: 1598, 1866, 1912, 2080, 2300, and/or 2424.
11. The engineered galactose oxidase of claim 1 , wherein said engineered galactose oxidase is purified.
12. A composition comprising at least one engineered galactose oxidase of claim 1 .
13. The engineered galactose oxidase of claim 1 , wherein said engineered galactose oxidase comprises substitutions as compared to SEQ ID NO: 1912 in said polypeptide sequence of F291Y, N375D, T453V, and T465L, and wherein the amino acid positions of said polypeptide sequence are numbered with reference to SEQ ID NO: 1912.
14. The engineered galactose oxidase of claim 1 , wherein said engineered galactose oxidase comprises substitutions as compared to SEQ ID NO: 2 in said polypeptide sequence of 291Y, 375D, 453V, and 465L, and wherein the amino acid positions of said polypeptide sequence are numbered with reference to SEQ ID NO: 2.
15. The engineered galactose oxidase of claim 1 , wherein said engineered galactose oxidase comprises substitutions as compared to SEQ ID NO: 2 in said polypeptide sequence of F291Y, N375D, T453V, and F465L, and wherein the amino acid positions of said polypeptide sequence are numbered with reference to SEQ ID NO: 2.